Professional Documents
Culture Documents
Ajay Gautam
BioPharma LatAm
November 2014
Mexico
1998
2009
2006
2012
50,000
100 countries
employees
Manufacturing in
Research across
16 countries
3 continents
$25.7bn sales
Approx. $4bn
#2
In China
Emerging Markets
$5.4bn sales
2013, Full Year Results
Oncology
Respiratory, Inflammation,
Autoimmune
Cardio-Metabolism
Content
Core TAs
Biologics
Small Molecules
Immunotherapies
Protein
engineering
Cambridge
Mlndal
Co-locate around
biologics/specialty care
Connections to Karolinska
Institute & Medicon Valley
Proximity to NIH,
Johns Hopkins
Topics
Looking forward
Improved
capabilities
Expanded
talent pool
Stronger
IP
- China:
- Russia:
- Brazil:
Scientific
expertise
Business model
Innovation
ecosystem
Talent pool
10
Innovation
IP
11
China
Israel
Korea
Singapore
High
Moderate
Low
12
China
Israel
Korea
Singapore
Russia
Brazil
India
Brazil
Turkey
Mexico
S Africa
Poland
India
Russia
Turkey
Mexico
S Africa
Poland
# of PhD
# of patents
# of clinical trials
China
India
Russia
China
Korea
Brazil
Russia
China
Korea
Israel
Brazil
Poland
Brazil
S Africa
Mexico
India
Israel
S Africa
India
Russia
Israel
Korea
Singapore
Poland
Turkey
Turkey
Mexico
Singapore
Poland
Turkey
S Africa
Mexico
Singapore
Topics
Looking forward
13
Today
14
Office of
Chief
Scientist
15
Early stage
funding
17
Topics
Looking forward
18
Russia
Taiwan
Israel
19
China
20
21
22
23
http://openinnovation.astrazeneca.com
24
Pharmacology Toolbox
Compounds with optimised pharmacological properties are available for preclinical research to explore
novel disease biology and advance scientific knowledge
Target Innovation
Do you have an innovative target idea for a drug discovery project? We may be able to help you
validate your idea, by providing access to our compound library
25
R&D Challenges
To expand our problem solving ecosystem, we are sharing key R&D hurdles and looking to collaborate
with and reward those who bring innovative solutions
Suggestion Box
Do you have an idea, technology, or suggestion that fits outside of the above mentioned collaboration
offerings?
26
Topics
Looking forward
27
1987
1994
2000
2012
29
30